[go: up one dir, main page]

ES2564252T3 - Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos - Google Patents

Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos Download PDF

Info

Publication number
ES2564252T3
ES2564252T3 ES11745672.3T ES11745672T ES2564252T3 ES 2564252 T3 ES2564252 T3 ES 2564252T3 ES 11745672 T ES11745672 T ES 11745672T ES 2564252 T3 ES2564252 T3 ES 2564252T3
Authority
ES
Spain
Prior art keywords
seq
lcdr1
lcdr2
hcdr1
hcdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11745672.3T
Other languages
English (en)
Inventor
Jirong Lu
Ying Tang
Ronald Bradley Demattos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2564252T3 publication Critical patent/ES2564252T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un anticuerpo monoclonal anti-N3pGlu Aß humano diseñado por ingeniería genética o fragmento de unión al antígeno del mismo, que comprende una región variable de cadena ligera (LCVR) y una región variable de cadena pesada (HCVR), en el que dicha LCVR comprende los polipéptidos LCDR1, LCDR2 y LCDR3, y HCVR comprende los polipéptidos HCDR1, HCDR2 y HCDR3 que se seleccionan entre: a) LCDR1 es KSSQSLLYSRGKTYLN (SEC ID Nº 3), LCDR2 es AVSKLDS (SEC ID Nº 4), LCDR3 es VQGTHYPFT (SEC ID Nº 5), HCDR1 es GYDFTRYYIN (SEC ID Nº 6), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8) y HCDR3 es EGITVY (SEC ID Nº 9); b) LCDR1 es KSSQSLLYSRGKTYLN (SEC ID Nº 3), LCDR2 es AVSKLDS (SEC ID Nº 4), LCDR3 es VQGTHYPFT (SEC ID Nº 5), HCDR1 es GYTFTRYYIN (SEC ID Nº 7), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8) y HCDR3 es EGTTVY (SEC ID Nº 10); c) LCDR1 es KSSQSLLYSRGKTYLN (SEC ID Nº 3), LCDR2 es AVSKLDS (SEC ID Nº 4), LCDR3 es VQGTHYPFT (SEC ID Nº 5), HCDR1 es GYTFTDYYIN (SEC ID Nº 40), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8) y HCDR3 es EGETVY (SEC ID Nº 41); d) LCDR1 es KSSQSLLYSRGKTYLN (SEC ID Nº 3), LCDR2 es AVSKLGS (SEC ID Nº 35), LCDR3 es VQGTHYPFT 5 (SEC ID Nº 5), HCDR1 es GYTFTRYYIN (SEC ID Nº 7), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8) y HCDR3 es EGTTVY (SEC ID Nº 10); y e) LCDR1 es KSTRSLLYSRSKTYLN (SEC ID Nº 45), LCDR2 es AVSKLDS (SEC ID Nº 4), LCDR3 es VQGTHYPFT (SEC ID Nº 5), HCDR1 es GYTFTDYYIN (SEC ID Nº 40), HCDR2 es WINPGSGNTKYNEKFKG (SEC ID Nº 8), y HCDR3 es EGVTVY (SEC ID Nº 46).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
    imagen2
ES11745672.3T 2010-08-12 2011-08-09 Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos Active ES2564252T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37302610P 2010-08-12 2010-08-12
US373026P 2010-08-12
PCT/US2011/046994 WO2012021469A1 (en) 2010-08-12 2011-08-09 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
ES2564252T3 true ES2564252T3 (es) 2016-03-21

Family

ID=44543826

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11745672.3T Active ES2564252T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
ES18150424T Active ES2764728T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos
ES15196358.4T Active ES2664128T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES18150424T Active ES2764728T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos
ES15196358.4T Active ES2664128T3 (es) 2010-08-12 2011-08-09 Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos

Country Status (39)

Country Link
US (2) US8679498B2 (es)
EP (3) EP2603523B1 (es)
JP (2) JP5980207B2 (es)
KR (1) KR101498833B1 (es)
CN (2) CN105111308B (es)
AU (1) AU2011289629B2 (es)
BR (1) BR112013004056B8 (es)
CA (1) CA2805114C (es)
CL (1) CL2013000390A1 (es)
CO (1) CO6670526A2 (es)
CR (1) CR20130016A (es)
CY (2) CY1120144T1 (es)
DK (3) DK3339323T3 (es)
DO (1) DOP2013000029A (es)
EA (1) EA023021B1 (es)
EC (1) ECSP13012436A (es)
ES (3) ES2564252T3 (es)
GT (1) GT201300036A (es)
HK (1) HK1180703A1 (es)
HR (3) HRP20160151T1 (es)
HU (2) HUE028678T2 (es)
IL (2) IL224030B (es)
LT (2) LT3042917T (es)
MA (1) MA34461B1 (es)
ME (3) ME03661B (es)
MX (2) MX342782B (es)
MY (2) MY163521A (es)
NO (1) NO3042917T3 (es)
NZ (2) NZ626665A (es)
PE (1) PE20130817A1 (es)
PH (1) PH12013500277A1 (es)
PL (3) PL3042917T3 (es)
PT (2) PT3339323T (es)
RS (3) RS59652B1 (es)
SG (2) SG10201509330XA (es)
SI (3) SI2603523T1 (es)
UA (1) UA107600C2 (es)
WO (1) WO2012021469A1 (es)
ZA (1) ZA201300437B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
EP3102611A4 (en) * 2014-02-03 2017-08-23 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
EP3693389B1 (en) * 2014-07-10 2024-09-04 Universität Zürich Immune-stimulating monoclonal antibodies against human interleukin-2
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
ES2901133T3 (es) * 2015-09-23 2022-03-21 Regeneron Pharma Anticuerpos biespecíficos anti-CD3 optimizados y usos de los mismos
IL260218B2 (en) 2016-01-11 2023-04-01 Novartis Ag Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
AR107783A1 (es) * 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
AR107774A1 (es) * 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI798751B (zh) * 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
JP2019530647A (ja) 2016-08-18 2019-10-24 イーライ リリー アンド カンパニー Ｂａｃｅ−１阻害剤と抗ｎ３ｐｇｌｕ ａベータ抗体の併用療法
AR110470A1 (es) * 2016-10-21 2019-04-03 Lilly Co Eli Terapia de combinación para tratar la enfermedad de alzheimer
MX2019004763A (es) 2016-10-28 2019-07-01 H Lundbeck As Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos.
MX2019004859A (es) 2016-10-28 2019-06-20 H Lundbeck As Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
ES2945165T3 (es) 2017-08-22 2023-06-28 Biogen Ma Inc Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
PL3723807T3 (pl) 2017-12-14 2022-01-24 H. Lundbeck A/S Leczenie skojarzone obejmujące podawanie 1h-pirazolo­[4,3-b]pirydyn
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
AU2020245031A1 (en) * 2019-03-26 2021-10-21 Janssen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-β and uses thereof
MX2022004311A (es) 2019-10-15 2022-05-10 Lilly Co Eli Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
WO2021257808A2 (en) * 2020-06-17 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
CN116547292A (zh) * 2020-10-02 2023-08-04 伊莱利利公司 用于减少抗体纯化过程中的宿主细胞蛋白质含量的方法和具有减少的宿主细胞蛋白质含量的抗体组合物
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
AU2022371475A1 (en) 2021-10-22 2024-05-09 Eli Lilly And Company O-glcnacase (oga) inhibitor combination therapy
CN118475609A (zh) 2021-10-29 2024-08-09 伊莱利利公司 靶向白细胞介素-34的化合物和方法
JP2024542999A (ja) 2021-10-29 2024-11-19 イーライ リリー アンド カンパニー インターロイキン－３４を標的とする化合物及び方法
AU2022376931A1 (en) 2021-10-29 2024-05-02 Eli Lilly Company Compounds and methods targeting interleukin-34
AR127484A1 (es) 2021-10-29 2024-01-31 Lilly Co Eli Compuestos y métodos dirigidos a interleucina-34
IL314657A (en) 2022-02-03 2024-09-01 Lilly Co Eli Regional tau imaging for diagnosing and treating alzheimer's disease
IL318102A (en) 2022-07-21 2025-02-01 Lilly Co Eli Pharmaceutical solutions of anti-n3pglu aβ antibodies and their uses
TW202440628A (zh) 2022-12-22 2024-10-16 瑞典商生物極公司 新抗體

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1911765A3 (en) 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
JP4851348B2 (ja) * 2004-02-23 2012-01-11 イーライ リリー アンド カンパニー 抗Ａβ抗体
KR101068289B1 (ko) * 2004-07-30 2011-09-28 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
AU2008242648B2 (en) * 2007-04-18 2013-09-12 Janssen Alzheimer Immunotherapy Prevention and treatment of cerebral amyloid angiopathy
JP2011522842A (ja) 2008-06-12 2011-08-04 アフィリス・アクチェンゲゼルシャフト パーキンソン病に関連する症状の治療のための化合物
EP2321348A2 (en) 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
KR101706789B1 (ko) * 2008-07-21 2017-02-14 프로비오드룩 아게 진단용 항체 검사법
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie

Also Published As

Publication number Publication date
CO6670526A2 (es) 2013-05-15
EP3339323A1 (en) 2018-06-27
EA023021B1 (ru) 2016-04-29
CN103068848B (zh) 2015-11-25
HUE028678T2 (en) 2016-12-28
KR20130051989A (ko) 2013-05-21
MY163521A (en) 2017-09-15
ES2764728T3 (es) 2020-06-04
HRP20180616T1 (hr) 2018-07-13
CN105111308A (zh) 2015-12-02
CA2805114C (en) 2017-12-05
DOP2013000029A (es) 2013-03-15
PL2603523T3 (pl) 2016-07-29
IL224030B (en) 2022-04-01
HK1180703A1 (zh) 2013-10-25
DK2603523T3 (en) 2016-03-21
BR112013004056B8 (pt) 2022-10-18
JP6395755B2 (ja) 2018-09-26
PE20130817A1 (es) 2013-07-18
JP5980207B2 (ja) 2016-08-31
ES2664128T3 (es) 2018-04-18
MY181969A (en) 2021-01-15
IL285226B2 (en) 2023-02-01
PT3042917T (pt) 2018-05-02
LT3042917T (lt) 2018-05-10
JP2013536191A (ja) 2013-09-19
CY1122458T1 (el) 2021-01-27
SI3339323T1 (sl) 2019-12-31
JP2016179985A (ja) 2016-10-13
EP3042917A1 (en) 2016-07-13
MA34461B1 (fr) 2013-08-01
DK3339323T3 (da) 2020-01-20
MX342782B (es) 2016-10-12
EP3042917B1 (en) 2018-02-21
HUE037524T2 (hu) 2018-09-28
CN103068848A (zh) 2013-04-24
SG10201509330XA (en) 2015-12-30
RS54685B1 (en) 2016-08-31
NZ626665A (en) 2016-04-29
NZ606095A (en) 2014-11-28
PL3339323T3 (pl) 2020-05-18
CY1120144T1 (el) 2018-12-12
EA201270813A1 (ru) 2013-05-30
NO3042917T3 (es) 2018-07-21
RS59652B1 (sr) 2020-01-31
AU2011289629B2 (en) 2014-07-03
MX355268B (es) 2018-04-11
SI3042917T1 (en) 2018-04-30
EP3339323B1 (en) 2019-11-13
PT3339323T (pt) 2020-01-14
DK3042917T3 (en) 2018-04-23
ZA201300437B (en) 2014-06-25
ME03032B (me) 2018-10-20
ME02352B (me) 2016-06-20
CL2013000390A1 (es) 2014-03-21
KR101498833B1 (ko) 2015-03-04
SG187586A1 (en) 2013-03-28
HRP20160151T1 (hr) 2016-03-11
WO2012021469A1 (en) 2012-02-16
CA2805114A1 (en) 2012-02-16
HRP20192233T1 (hr) 2020-03-06
SI2603523T1 (sl) 2016-04-29
UA107600C2 (uk) 2015-01-26
PH12013500277A1 (en) 2017-04-21
PL3042917T3 (pl) 2018-07-31
RS57026B1 (sr) 2018-05-31
ECSP13012436A (es) 2013-03-28
LT3339323T (lt) 2020-02-10
EP2603523B1 (en) 2016-01-27
US8679498B2 (en) 2014-03-25
IL285226A (en) 2021-09-30
BR112013004056B1 (pt) 2022-05-17
GT201300036A (es) 2014-07-16
CN105111308B (zh) 2019-03-12
BR112013004056A2 (pt) 2020-08-04
ME03661B (me) 2020-07-20
AU2011289629A1 (en) 2013-02-14
US20130142806A1 (en) 2013-06-06
US8961972B2 (en) 2015-02-24
CR20130016A (es) 2013-03-21
EP2603523A1 (en) 2013-06-19
IL285226B (en) 2022-10-01
US20140065138A1 (en) 2014-03-06
MX2013001716A (es) 2013-10-28

Similar Documents

Publication Publication Date Title
ES2564252T3 (es) Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
ES2656000T3 (es) Anticuerpos frente a CGRP
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
CU24636B1 (es) Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
JP2018021031A5 (es)
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
AR083747A1 (es) Anticuerpos anti-il-23
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
NZ740221A (en) St2l antagonists and methods of use
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20130226A1 (es) Anticuerpos hacia gdf8 humano